As of 2025-09-18, the EV/EBITDA ratio of Mersana Therapeutics Inc (MRSN) is 0.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRSN's latest enterprise value is -23.94 mil USD. MRSN's TTM EBITDA according to its financial statements is -70.56 mil USD. Dividing these 2 quantities gives us the above MRSN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 15.0x | 13.6x |
| Forward P/E multiples | 15.1x - 41.5x | 19.2x |
| Fair Price | (201.02) - (199.89) | (219.97) |
| Upside | -2911.4% - -2895.6% | -3176.4% |
| Date | EV/EBITDA |
| 2025-09-16 | 0.34 |
| 2025-09-15 | 0.34 |
| 2025-09-12 | 0.34 |
| 2025-09-11 | 0.32 |
| 2025-09-10 | 0.33 |
| 2025-09-09 | 0.30 |
| 2025-09-08 | 0.35 |
| 2025-09-05 | 0.36 |
| 2025-09-04 | 0.34 |
| 2025-09-03 | 0.35 |
| 2025-09-02 | 0.35 |
| 2025-08-29 | 0.33 |
| 2025-08-28 | 0.30 |
| 2025-08-27 | 0.31 |
| 2025-08-26 | 0.30 |
| 2025-08-25 | 0.30 |
| 2025-08-22 | 0.30 |
| 2025-08-21 | 0.27 |
| 2025-08-20 | 0.33 |
| 2025-08-19 | 0.33 |
| 2025-08-18 | 0.32 |
| 2025-08-15 | 0.34 |
| 2025-08-14 | 0.32 |
| 2025-08-13 | 0.36 |
| 2025-08-12 | 0.42 |
| 2025-08-11 | 0.42 |
| 2025-08-08 | 0.40 |
| 2025-08-07 | 0.38 |
| 2025-08-06 | 0.37 |
| 2025-08-05 | 0.35 |
| 2025-08-04 | 0.36 |
| 2025-08-01 | 0.38 |
| 2025-07-31 | 0.36 |
| 2025-07-30 | 0.37 |
| 2025-07-29 | 0.35 |
| 2025-07-28 | 0.36 |
| 2025-07-25 | 0.30 |
| 2025-07-24 | 0.28 |
| 2025-07-23 | 0.13 |
| 2025-07-22 | 0.20 |
| 2025-07-21 | 0.21 |
| 2025-07-18 | 0.22 |
| 2025-07-17 | 0.20 |
| 2025-07-16 | 0.25 |
| 2025-07-15 | 0.27 |
| 2025-07-14 | 0.24 |
| 2025-07-11 | 0.24 |
| 2025-07-10 | 0.17 |
| 2025-07-09 | 0.25 |
| 2025-07-08 | 0.27 |